|
|
||||||||
Cardiology Research Laboratory, Departments of Medicine, Pharmacology, and Toxicology, London Health Sciences Centre, University of Western Ontario, London, Ontario, Canada N6A 4G5
| |
ABSTRACT |
|---|
|
|
|---|
L-Arginine crosses the cell membrane primarily through the
system y+ transporter. The aim of this study was to
investigate the role of L-arginine transport in nitric
oxide (NO) production in aortas of rats with heart failure induced by
myocardial infarction. Tumor necrosis factor-
levels in aortas of
rats with heart failure were six times higher than in sham rats
(P < 0.01). L-Arginine uptake was
increased in aortas of rats with heart failure compared with sham rats
(P < 0.01). Cationic amino acid transporter-2B and
inducible (i) nitric oxide synthase (NOS) expression were increased in
aortas of rats with heart failure compared with sham rats
(P < 0.05). Aortic strips from rats with heart failure
treated with L-arginine but not D-arginine
increased NO production (P < 0.05). The effect of
L-arginine on NO production was blocked by
L-lysine, a basic amino acid that shares the same
system y+ transporter with
L-arginine, and by the NOS inhibitor
NG-nitro-L-arginine methyl
ester (L-NAME). Treatment with L-lysine and
L-NAME in vivo decreased plasma nitrate and nitrite
levels in rats with heart failure (P < 0.05). Our data
demonstrate that NO production is dependent on iNOS activity and
L-arginine uptake and suggest that L-arginine
transport plays an important role in enhanced NO production in heart failure.
cationic amino acid transporter; vascular biology; myocardial dysfunction
| |
INTRODUCTION |
|---|
|
|
|---|
L-ARGININE IS A CATIONIC and dibasic amino acid that is semiessential in the mammalian diet. Nitric oxide synthase (NOS) uses L-arginine as its substrate during the production of nitric oxide (NO). NO is produced from the guanidino group of L-arginine in an NADPH-dependent reaction catalyzed by a family of NOS enzymes (23). There are at least three distinct isoforms of NOS, derived from separate genes: neural NOS (nNOS or NOS I), inducible NOS (iNOS or NOS II), and endothelial NOS (eNOS or NOS III). Although eNOS and nNOS are calcium-dependent enzymes, iNOS is usually induced by cytokines, and its enzyme activity is calcium independent.
L-Arginine is transported into cells from the extracellular space primarily through the specific amino acid transport system y+, now known as the cationic amino acid transporter (CAT; see Ref. 5). System y+ is a facilitative process that is Na+ independent and pH insensitive. Four members of the CAT family in system y+ have recently been cloned and identified. CAT-1 is constitutively expressed and is present in a wide range of tissues (19, 29). CAT-2A and CAT-2B are more limited in their tissue distribution and have been reported to be physiologically regulated. CAT-3 is a brain tissue-specific CAT. It is of interest that analogs of L-arginine have potent inhibitory effects on system y+ (2). For instance, L-homoarginine, differing from L-arginine by the presence of a CH2 group, is a strong competitive inhibitor of system y+ action. Other cationic amino acids such as L-lysine also competitively inhibit L-arginine transport via system y+.
Heart failure is associated with increases in peripheral resistance of
the vasculature. This augmented vascular resistance is detrimental and
may contribute to the high mortality of heart failure in the late
phases of the disease. Studies have demonstrated that, although
endothelium-dependent, NO-mediated vasodilation is decreased (7,
9), basal NO production is increased in heart failure (8,
13). The increased basal NO production may be due to increased
iNOS activity in the myocardium and vasculature of heart failure
(14, 16). Consequently, it is possible that consumption of
intracellular L-arginine may be increased as a result of
increased NO production in heart failure. However, it is not known if
L-arginine transport is increased in the vasculature of
heart failure. Cytokines such as TNF-
are increased in patients with
heart failure (14, 21). Recent studies have demonstrated that cytokines induce CAT-2 gene expression in cardiac myocytes and
vascular smooth muscle cells (11, 26). It is not known if
CAT-2 expression is increased in heart failure. We hypothesized that
CAT-2 expression and L-arginine uptake are increased and contribute to the increased NO production in aortas of heart failure. To test this hypothesis, we employed a rat model of heart failure induced by myocardial infarction and investigated the role of L-arginine transport in NO production in the aortas of rats
with heart failure.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Animals. Experiments were initially conducted on male Sprague-Dawley rats (175-200 g). All animals were maintained on normal rat chow and were given water ad libitum in a 12:12-h light-dark cycle. The animals were caged individually after the initial surgical operation. This study protocol was approved by the Council on Animal Care at the University of Western Ontario.
Induction of heart failure. Heart failure was induced by left coronary artery ligation, as described previously (8, 9). Experiments were performed 8 wk after this surgery. Hemodynamic measurements were made under pentobarbital sodium anesthesia (50 mg/kg ip), as previously described (8, 9). Briefly, left ventricular end-diastolic pressure and left ventricular contractility were assessed by inserting a heparinized polyethylene catheter (PE-50; Becton-Dickson, Sparks, MD) in the left ventricle via the right carotid artery. The maximal rates of pressure development and relaxation were assessed with a pressure signal connected to a differentiator. Mean arterial pressure was evaluated using the same catheter in the right carotid artery, after removal from the left ventricle. All pressures and heart rates were measured with a Stratham pressure transducer (model P10 EZ) connected to a pressure monitor and were recorded on a Gould recorder (model 2400 S). All measurements were made in the anesthetized state after an equilibration period (20-30 min) for stabilization after completion of cannulations. At the end of the experiments, the animal was killed, and the heart weight, left ventricular volume and infarct size were measured as we have described previously (8, 9).
Tumor necrosis factor-
ELISA.
Tumor necrosis factor-
(TNF-
) levels in aortas were measured
using a solid-phase sandwich ELISA (Rat TNF-
Ultrasensitive Immunoassay Kit; Biosource International, Camarillo, CA) according to
the manufacturer's instructions. Briefly, excised aortas were placed
in ice-cold PBS (pH 7.4) containing protease inhibitors (0.25 mM
phenylmethylsulfonyl fluoride, 4.5 µM leupeptin, and 5 µM
aprotinin) and mechanically homogenized for 1 min (Polytron Homogenizer; Pro Scientific, Monroe, CT). Homogenates were subsequently centrifuged (10,000 g; 10 min) at 4°C. After the
determination of protein concentration using the Lowry method, aliquots
(100 µl) of lysates corresponding to 200 µg of total protein were
added to microtiter plates coated with anti-TNF-
antibody. Next, a biotinylated antibody specific for TNF-
was added. Subsequently, streptavidin-peroxidase was added; the streptavidin-peroxidase binded
to the biotinylated antibody. Finally, a stabilized chromogen was added
for color development, and optical density was measured at 450 nm. The
amount of TNF-
in each sample was determined from a linearized
standard curve and was expressed as picograms per milligram of total protein.
L-Arginine uptake assay.
Uptake of radioactive L-arginine in the rat aorta was
measured according to previously described methods with modifications (1, 12). Immediately after the rat was killed, the aorta was carefully excised from the left renal artery in the abdomen to the
aortic valve ring and placed in ice-cold Na+-free,
choline-containing Krebs bicarbonate. After the removal of all adherent
adventitial tissue, the vessel was cut into six segments ~10-15
mm in length. Each segment was cut longitudinally in half, blotted dry,
and weighed. In some experiments, the aortic tissues were incubated at
37°C for 3 h to deplete intracellular L-arginine
(zero-trans conditions) before the uptake assay
(15). To measure total uptake, aortic segments were
incubated with 2 ml of L-[3H]arginine
(10-500 µM) with specific activities of 0.5 µCi/ml. For
nonspecific uptake measurements, aortic segments were incubated with
L-[3H]arginine and 10 mM
L-homoarginine, which competitively inhibits L-arginine uptake by system y+ (12,
15). In some experiments,
L-[3H]arginine uptake was competitively
inhibited using L-lysine (10-800 µM). In other
experiments, L-[3H]arginine was replaced with
L-[3H]lysine, maintaining a constant specific
activity of 0.5 µCi/ml, and L-[3H]lysine
uptake was in turn competitively inhibited using L-arginine (10-800 µM). The aortic segments were incubated in an atmosphere of 5% CO2 and 95% O2 with continuous shaking
at 37°C. After a 40-min incubation period, the segments were removed
from the radioactive buffer and washed three times with 1-ml aliquots
of ice-cold Na+-free, choline-containing Krebs bicarbonate
solution. Subsequently, each segment of the aorta was placed in a tube
containing 2% (vol/vol) SDS solution and was heated at 100°C for
1 h. Radioactivity of the ambient incubation buffer and SDS
solutions was measured by
-scintillation counting (Beckman,
Mississauga, ON).
Determination of NOS activity. The activity of the NOS was determined through the conversion of L-[3H]arginine to L-[3H]citrulline based on modifications of previously described methods (25). The protein content of the tissue was measured by the method of Bradford (3). The activity of the calcium-dependent NOS was determined from the difference between the L-[3H]citrulline produced from samples containing calmodulin/calcium and those containing EDTA/EGTA. The activity of the calcium-independent NOS was determined as the total L-[3H]citrulline production from the aforementioned samples containing EDTA/EGTA.
RT-PCR.
Total RNA isolated from fresh aortic tissue with Trizol reagent was
reverse transcribed into first-strand cDNA with the utilization of the
Moloney murine leukemia virus RT system. Evaluation of CAT-1 and CAT-2B
mRNA expression was performed based on a "primer-dropping" method
of PCR (30). To minimize competition for PCR substrates, iNOS and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were amplified independently. Target gene accession numbers, reaction primer
sequences, cycle numbers, and annealing temperatures are summarized in
Table 1. Samples were then
electrophoresed in gels containing ethidium bromide, illuminated, and
subsequently analyzed via computer densitometry. All densitometric data
were standardized to GAPDH mRNA.
|
iNOS Western blot analysis.
iNOS protein expression in aortas was determined by Western blot
analysis. Total proteins were extracted from aortas as described for
the TNF-
ELISA. To each sample, SDS was added to a final concentration of 0.1%. Protein concentration was determined by the
method of Lowry. Aliquots of lysate corresponding to 100 µg of total
protein were mixed with loading buffer (1×) and boiled for 5 min. The
samples were separated by SDS-PAGE (6%
acrylamide/bisacrylamide). Proteins were transferred to
nitrocellulose membranes (Hybond; Amersham Life Sciences, Oakville, ON)
in the presence of glycine/methanol transfer buffer using the Mini
Protean II Transfer System (Bio-Rad). Membranes were blocked in 5%
nonfatty dry milk powder in PBS (pH 7.6) overnight at 4°C.
Subsequently, the membranes were exposed to anti-mouse iNOS
(Transduction Laboratories, Franklin Lakes, NJ) at a
concentration of 1:500 in 2.5% milk in PBS (2 h; room temperature).
The membranes were washed with PBS (pH 7.6) and 0.05% Tween 20 and
exposed 1:2,000 to horseradish peroxidase-conjugated anti-mouse IgG in
2.5% milk in PBS (2 h; room temperature). After the wash, enhanced
chemiluminscence detection reagents were employed to visualize
peroxidase reaction products. iNOS was detected as a 120-kDa band.
Nitrate/nitrite measurements. Plasma nitrate/nitrite (NOx) levels were measured using Aspergillus nitrate reductase and the Griess reagent as we have described previously (8). The Griess reagent (2% sulfanilamide and 0.2% naphthylenediamine both in 5% phosphoric acid, 1:1 mixture) was used to react with nitrite in the sample, and the absorbance was determined at 540 nm with a spectrophotometer. The concentrations were calculated from a linearized standard curve derived from solutions of NaNO3 (5-100 µmol/l). All animals were fasted for 18 h before the collection of plasma to eliminate any effects that rat chow nitrates and nitrites could potentially have on these experiments. Animals were given water containing 10% D-glucose during this fasting period.
In vitro NO production in aortas. The in vitro aortic NO production was measured according to a previously described method with modifications (28). Briefly, fresh thoracic aortas from rats with heart failure were isolated and placed in sterilized ice-cold PBS (pH 7.4). Under sterile conditions, aortas were cleared of adventitial tissue and washed three times in PBS. Subsequently, the aortas were cut longitudinally into four segments. After each segment was weighed individually, 1 ml of MEM culture medium alone or supplemented with 1 mM L-arginine, 1 mM L-arginine plus 10 mM L-lysine, 1 mM L-arginine plus 1 mM NG-nitro-L-arginine methyl ester (L-NAME), or 1 mM D-arginine was separated into aliquots into four culture dishes. Aortic segments were transferred to the culture dishes and incubated at 37°C under atmospheric conditions of 5% CO2 and 95% air. After a 24-h incubation time, the culture medium of each dish was collected in separate microcentrifuge tubes. The medium of each tube was subsequently dried (model SVC100H; Savant Speed Vacuum Concentrator), and the resulting pellets were redissolved with 100 µl of distilled water. Total nitrite and nitrate contained in each sample was measured using Griess reagent as described above.
Reagents. The Aspergillus nitrate reductase was purchased from Boehringer Mannheim (Laval, QU), and the 550° silicone oil was obtained from Dow Corning (London, ON). The L-[2,3,4,5-3H]arginine was purchased from Amersham Life Sciences. The L-[3,4-3H]lysine was from ICN Pharmaceuticals (Irvine, CA). MEM culture medium without phenyl red and without L-glutamine, TRIzol reagent, Moloney murine leukemia virus, and Taq polymerases were purchased from GIBCO-BRL (Burlington, ON). All other chemicals were purchased from Sigma (Oakville, ON).
Statistical analysis. Data are expressed as means ± SE. Differences between heart failure and sham control groups were compared using unpaired Student's t-test or Mann-Whitney rank sum test. For multigroup comparisons, ANOVA followed by the Student-Newman-Keuls test was performed (Sigma Stat version 1.1; Jandel). A two-tailed P value <0.05 was considered statistically significant.
| |
RESULTS |
|---|
|
|
|---|
Characterization of L-arginine uptake in normal rat
aortas.
Incubation of normal rat aortas with
L-[3H]arginine resulted in a time- and
concentration-dependent increase in L-arginine uptake that
was Na+ independent (Fig. 1,
A and B). Peak uptake of
L-[3H]arginine was ~40 min after
incubation. Hence, a 40-min incubation time was used for all subsequent
experiments. Uptake of L-[3H]arginine was
similar in different segments from the aortic root to the abdominal
aorta, suggesting that there is no regional difference in
L-arginine uptake in aortas (Fig. 1C).
L-[3H]arginine uptake was inhibited
completely by L-lysine in a concentration-dependent manner,
and vice versa uptake of L-[3H]lysine was
inhibited completely by increasing concentrations of
L-arginine in rat aortas (Fig.
2, A and
B).
|
|
General characteristics of heart failure.
The infarct size of coronary artery-ligated rats was 42 ± 2%
(n = 23) of the left ventricle. No myocardial
infarction was observed in sham-operated control rats
(n = 26). Rats with heart failure had signs of cardiac
dilatation, pulmonary and hepatic congestion, pleural effusion, and
ascites. In heart failure, the weight of the whole heart and left and
right ventricles was increased significantly compared with
sham-operated rats (P < 0.01), whereas body weight was
similar between the two groups [P = not significant (NS); Table 2]. Ten heart failure and 10 sham-operated rats were chosen randomly for hemodynamic measurements.
Cardiac index was decreased, whereas left ventricular end-diastolic
pressure was significantly increased in rats with heart failure
(P < 0.01; Table 2). These hemodynamic changes in
coronary artery-ligated rats were characteristic of clinical heart
failure.
|
TNF-
levels in aortas of rats with heart failure.
To determine that heart failure was associated with altered cytokine
levels, aortic TNF-
was assessed by ELISA. Indeed, average levels of
TNF-
in the aortic tissue of rats with heart failure were six times
higher than in sham-operated rats (P < 0.01; Fig. 3).
|
L-Arginine uptake in aortas of rats with heart
failure.
To examine whether the functional transport of L-arginine
is altered in aortas of rats with heart failure, uptake studies of
L-[3H]arginine were carried out. Uptake
experiments were performed with 200 µM L-arginine, a
concentration reflective of the basal L-arginine plasma
level in normal rats as we demonstrated in our previous studies
(8). The data from endothelium-intact aortas showed a 40%
increase in L-[3H]arginine uptake in rats
with heart failure compared with sham-operated controls
(P < 0.01; Fig. 4).
Removal of endothelium from aortas of rats with heart failure
significantly reduced L-[3H]arginine uptake
(P < 0.05; Fig. 4).
|
CAT mRNA expression in aortas of rats with heart failure.
PCR reactions were carried out at linear amplifications for CAT-1,
CAT-2B, and GAPDH. With the use of a primer-dropping method, two
distinct bands coamplified from equal aliquots of cDNA were observed
for each aortic sample (Fig. 5,
A and B). CAT-1-to-GAPDH density ratios revealed
no significant differences between rats with heart failure and sham
rats (P = NS; Fig. 5D). However, the CAT-2B-to-GAPDH density ratio was significantly increased in aortas of
heart failure compared with sham-operated controls (P < 0.05; Fig. 5E). Interestingly, GAPDH levels seem to vary
with the amount of CAT-2B present, where greater amounts of CAT-2B
amplification seem to compete with GAPDH coamplification. To confirm
that equal amounts of cDNA were being amplified in each sample, GAPDH
was amplified alone for 19 cycles. Indeed, it was demonstrated that similar amounts of cDNA were present in each sample undergoing the
coamplification procedure (Fig. 5C).
|
Expression of iNOS protein and activity in aortas of rats with
heart failure.
The cDNA of iNOS and GAPDH from aortas was amplified by PCR. PCR
products of iNOS and GAPDH are shown in Fig.
6. The density ratios of iNOS/GAPDH were
increased significantly in heart failure compared with sham controls
(P < 0.05; Fig. 6D). Additionally, marked
iNOS protein expression was observed in aortas from rats with heart
failure compared with sham controls (Fig. 6C).
Calcium-dependent and -independent NOS activities were determined in
aortas by the L-arginine-L-citrulline
conversion assay. Calcium-dependent NOS activity was decreased in heart
failure (P < 0.05), whereas calcium-independent NOS
activity was increased in heart failure compared with sham-operated rats (P < 0.05; Fig. 6E).
|
Effects of L-arginine transport on NO production in
heart failure.
To examine the role of L-arginine uptake in NO production,
aortic segments from rats with heart failure were treated in culture with supplemental L-arginine, or with
L-arginine plus L-lysine, a competitive
inhibitor of L-arginine uptake through system
y+. Segments treated with D-arginine or in the
culture medium alone were used as controls. Culture medium from the
segments containing supplemental L-arginine demonstrated a
significant increase in NOx levels compared with control
segments (278 ± 21 vs. 82 ± 24 pmol/mg aortic tissue,
P < 0.05; Fig. 7). This
effect of L-arginine was inhibited completely by
L-lysine and L-NAME. D-Arginine is not a substrate of NOS nor is it transported through system
y+; moreover, this enantiomer did not alter NOx
levels in the medium compared with the control segments
(P = NS; Fig. 7). When the endothelium was removed,
L-arginine did not increase NOx production in
the aortas of rats with heart failure (P = NS; Fig. 7).
|
Plasma nitrate and nitrite levels in heart failure.
Plasma NOx levels were measured in rats with heart failure
and sham-operated controls to assess total NO production. To eliminate the effects of diet on NOx measurements, both rats with
heart failure and sham rats were fasted for 18 h before blood
samples were taken. During the fasting period, 10% glucose as drinking water was accessible to all rats. There was a greater than twofold increase in plasma NOx levels in rats with heart failure
compared with sham-operated controls (P < 0.05; Fig.
8). Treatment with L-lysine
(9.1 g/l) or L-NAME (100 mg/l) in 10% glucose drinking water during the 18-h fasting period significantly decreased plasma NOx levels in rats with heart failure (P < 0.05; Fig. 8).
|
| |
DISCUSSION |
|---|
|
|
|---|
In the present study, we demonstrated for the first time that functional L-arginine uptake and CAT-2B expression are significantly increased in aortas of rats with heart failure. We also demonstrated that NO production and iNOS expression are increased in aortas of rats with heart failure. Furthermore, selective inhibition of L-arginine uptake decreases NO production in aortas and plasma NOx levels in heart failure. These results suggest that upregulation of both L-arginine uptake and iNOS activity is required for increased NO production in rats with heart failure.
Uptake of cationic amino acids in mammalian cells occurs primarily through system y+ (5). Studies have shown that anywhere from 70 to 90% of the measurable uptake of L-arginine in pulmonary endothelial cells occurs via system y+ (12). In the present study, the incubation buffers containing Na+ or free of Na+ demonstrated similar uptake in rat aortas. L-Arginine uptake was inhibited competitively by increasing concentrations of another basic amino acid, L-lysine, which is transported via system y+ but does not interfere with metabolic pathways of L-arginine (2, 12). Furthermore, L-arginine uptake was decreased markedly after removal of the endothelium. The results suggest that L-arginine uptake in rat aortas is through system y+ and that the endothelium is the major site of uptake. In rats with heart failure, aortic L-arginine uptake was increased. When the endothelium was removed, L-arginine uptake was decreased, suggesting that endothelium contributes significantly to the increased L-arginine uptake in the aorta of heart failure.
Transporters responsible for L-arginine uptake have recently been cloned and identified. CAT-1 mRNA expression has been demonstrated to be ubiquitous in mammalian tissue, whereas CAT-2 mRNA expression has been reported to be physiologically regulated (11, 22). Furthermore, CAT-1 and CAT-2B isoforms are high-affinity transporters of system y+, whereas CAT-2A is a low-affinity transporter (6). This investigation evaluated mRNA expression of the high-affinity CAT-1 and CAT-2B transporters. We demonstrated that both CAT-1 and CAT-2B transporters were present in the rat aortas. Although CAT-1 mRNA expression was not altered, CAT-2B mRNA expression was significantly increased in the aortas of rats with heart failure. These data suggest that increased expression of CAT-2B may contribute to the increased L-arginine uptake in the aortas of rats with heart failure.
Interestingly, Hanssen et al. (15) have recently demonstrated that L-arginine uptake is increased in erythrocytes of patients with heart failure. Although eNOS protein has been demonstrated to be present in erythrocytes by some studies, the significance of NO production by erythrocytes is still not clear (4). In a separate study, we also demonstrated an increased L-arginine uptake in erythrocytes of rats with heart failure (unpublished data). Thus changes of L-arginine uptake in erythrocytes seem to parallel those of aortas in heart failure. However, the biochemical pathways of L-arginine, especially the contribution of the L-arginine/NO pathway in erythrocytes, remains to be determined.
Heart failure is associated with dysfunction of the endothelium. Decreased endothelium-dependent relaxation has been documented in the peripheral arteries of a pacing-induced heart failure dog model (20) and in thoracic aortas and hindquarter resistance arteries in the infarction-induced heart failure rat model by numerous investigators, including ourselves (7-9). In the present study, calcium-dependent NOS activity was also decreased in the aortas of these rats with heart failure, suggesting that the attenuated vasodilation is due to a decrease of eNOS activity. Paradoxically, plasma nitrate and nitrite, stable metabolites of NO, were increased significantly, suggesting increased basal NO production. We further demonstrated that iNOS mRNA and protein expression and iNOS activity were increased in aortas of rats with heart failure. Our data suggest that the increased iNOS expression and activity contribute to increased NO production in this heart failure rat model.
The role of L-arginine transport in NO production in the aortas of heart failure has not been demonstrated previously. In the present study, aortic segments from rats with heart failure were treated with D-arginine and L-arginine with and without L-lysine, a competitive inhibitor of L-arginine uptake through system y+. A novel finding of our study is that competitive inhibition of L-arginine uptake by L-lysine decreases NO production in aortas of rats with heart failure. The results indicate that the iNOS enzyme relies on a continuous L-arginine supply from the extracellular compartment, and L-arginine transport is essential for the enhanced NO production as a result of increased iNOS expression. L-NAME inhibits NOS activity without any effects on L-arginine transport (2). We further demonstrated that L-NAME and L-lysine independently inhibited NO production in aortas in vitro and decreased plasma nitrate and nitrite levels in vivo in rats with heart failure. These data strongly suggest that increased activities of both iNOS and L-arginine uptake are required for increased NO production in the aortas of rats with heart failure.
Mechanisms of the increased iNOS and CAT-2B expression in heart failure
are still not fully understood. Cytokines such as TNF-
have been
implicated in the pathogenesis of many heart diseases, including acute
myocardial infarction (18). In patients with heart
failure, circulating levels of TNF-
are elevated markedly (21). Furthermore, strong immunoreactivity for TNF-
colocalizes with iNOS in myocardial tissue of patients with dilated
cardiomyopathy, suggesting that TNF-
is associated with iNOS
expression (14). We recently showed that TNF-
induces
iNOS expression in cultured neonatal cardiomyocytes (27).
Studies have demonstrated that expression of CAT-2 mRNA is increased in
vascular smooth muscle cells, cardiac myocytes, and activated
macrophages upon treatment with cytokines (11, 26). In the
present study, we demonstrated for the first time that TNF-
levels
were increased in the aortas of rats with heart failure compared with
sham controls. Our data suggest that increased production of cytokines
may play an important role in iNOS and CAT-2B induction in the aortas
of heart failure. Other factors may also be involved in the complex
regulation of iNOS and CAT-2B induction in heart failure. Among these,
activation of ANG II and
-adrenergic receptors, activation of
protein kinase C isoforms, and increases in cAMP, all of which are
important components of the neurohumoral activation characteristic of
heart failure, may promote both iNOS and CAT-2B expression (17,
22, 24). Infiltration of macrophages expressing iNOS represents another mechanism whereby iNOS activity may be increased in heart failure (10). Thus increased cytokines and the associated
promoting factors and activated macrophages may contribute
significantly to the increased iNOS and CAT-2B expression in heart failure.
In summary, the present study demonstrated that in rats with heart
failure TNF-
levels, functional L-arginine uptake, and molecular expression of CAT-2B are increased in aortas. We also demonstrated that basal NO production and aortic iNOS expression are
increased. Furthermore, selective inhibition of L-arginine uptake decreases NO production in aortas and plasma NOx
levels. These results suggest that upregulation of both
L-arginine uptake and iNOS activity is associated with
increased NO production in rats with heart failure. Because increased
NO production is dependent on increased L-arginine uptake,
we conclude that L-arginine transport plays an important
role in enhanced NO production in heart failure.
| |
ACKNOWLEDGEMENTS |
|---|
This study was supported by Grants B3351 and T4045 from the Heart and Stroke Foundation of Ontario. P. B. Stathopulos was supported in part by a Graduate Scholarship from the Internal Research Fund, London Health Sciences Centre, London, Ontario, Canada. Q. Feng was supported by a Research Career Award in the Health Sciences from the Pharmaceutical Manufacturers Association of Canada Health Research Foundation and the Medical Research Council of Canada.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: Q. Feng, Dept of Medicine, London Health Sciences Centre, Victoria Campus, 375 South St., London, Ontario, Canada N6A 4G5 (E-mail: qfeng{at}julian.uwo.ca).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 23 March 2000; accepted in final form 31 August 2000.
| |
REFERENCES |
|---|
|
|
|---|
1.
Abbott, RE,
and
Schachter D.
Regional differentiation in rat aorta: L-arginine metabolism and cGMP content in vitro.
Am J Physiol Heart Circ Physiol
266:
H2287-H2295,
1994
2.
Bogle, RG,
Moncada S,
Pearson JD,
and
Mann GE.
Identification of inhibitors of nitric oxide synthase that do not interact with the endothelial cell L-arginine transporter.
Br J Pharmacol
105:
768-770,
1992[ISI][Medline].
3.
Bradford, MM.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal Biochem
72:
248-254,
1976[ISI][Medline].
4.
Chen, LY,
and
Mehta JL.
Evidence for the presence of L-arginine-nitric oxide pathway in human red blood cells: relevance in the effects of red blood cells on platelet function.
J Cardiovasc Pharmacol
32:
57-61,
1998[ISI][Medline].
5.
Christensen, HN.
Role of amino acid transport and counter-transport in nutrition and metabolism.
Physiol Rev
70:
43-77,
1990
6.
Closs, EI,
Lyons CR,
Kelly C,
and
Cunningham JM.
Characterization of the third member of the MCAT family of cationic amino acid transporters. Identification of a domain that determines the transport properties of the MCAT proteins.
J Biol Chem
268:
20796-20800,
1993
7.
Drexler, H,
and
Lu W.
Endothelial dysfunction of hindquarter resistance vessels in experimental heart failure.
Am J Physiol Heart Circ Physiol
262:
H1640-H1645,
1992
8.
Feng, Q,
Fortin AJ,
Lu X,
and
Arnold JMO
Effects of L-arginine on endothelial and cardiac function in rats with heart failure.
Eur J Pharmacol
376:
37-44,
1999[ISI][Medline].
9.
Feng, Q,
Lu XR,
Fortin AJ,
Pettersson A,
Hedner T,
Kline RL,
and
Arnold JMO
Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure.
Cardiovasc Res
37:
667-675,
1998
10.
Fukuchi, M,
Hussain SNA,
and
Giaid A.
Heterogeneous expression and activity of endothelial and inducible nitric oxide synthases in end-stage human heart failure.
Circulation
98:
132-139,
1998
11.
Gill, DJ,
Low B,
and
Grigor MR.
Interleukin-1b and tumor necrosis factor-a stimulate the CAT-2 gene of the L-arginine transporter in cultured vascular smooth muscle cells.
J Biol Chem
271:
11280-11283,
1996
12.
Greene, B,
Pacitti AJ,
and
Souba WW.
Characterization of L-arginine transport by pulmonary artery endothelial cells.
Am J Physiol Lung Cell Mol Physiol
264:
L351-L356,
1993
13.
Habib, F,
Dutka D,
Crossman D,
Oakley CM,
and
Cleland JG.
Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism?
Lancet
344:
371-373,
1994[ISI][Medline].
14.
Habib, FM,
Springall DR,
Davies GJ,
Oakley CM,
Yacoub MH,
and
Polak JM.
Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy.
Lancet
347:
1151-1155,
1996[ISI][Medline].
15.
Hanssen, H,
Brunini TM,
Conway M,
Banning AP,
Roberts NB,
Mann GE,
Ellory JC,
and
Mendes Ribeiro AC.
Increased L-arginine transport in human erythrocytes in chronic heart failure.
Clin Sci (Lond)
94:
43-48,
1998.
16.
Haywood, GA,
Tsao PS,
Von LHE,
Mann MJ,
Keeling PJ,
Trindade PT,
Lewis NP,
Byrne CD,
Rickenbacher PR,
Bishopric NH,
Cooke JP,
McKenna WJ,
and
Fowler MB.
Expression of inducible nitric oxide synthase in human heart failure.
Circulation
93:
1087-1094,
1996
17.
Ikeda, U,
Murakami Y,
Kanbe T,
and
Shimada K.
Alpha-adrenergic stimulation enhances inducible nitric oxide synthase expression in rat cardiac myocytes.
J Mol Cell Cardiol
28:
1539-1545,
1996[ISI][Medline].
18.
Irwin, MW,
Mak S,
Mann DL,
Qu R,
Penninger JM,
Yan A,
Dawood F,
Wen WH,
Shou Z,
and
Liu P.
Tissue expression and immunolocalization of tumor necrosis factor-a in postinfarction dysfunctional myocardium.
Circulation
99:
1492-1498,
1999
19.
Kim, JW,
Closs EI,
Albritton LM,
and
Cunningham JM.
Transport of cationic amino acids by the mouse ecotropic retrovirus receptor.
Nature
352:
725-728,
1991[Medline].
20.
Kiuchi, K,
Sato N,
Shannon RP,
Vatner DE,
Morgan K,
and
Vatner SF.
Decreased
-adrenergic receptor- and endothelium-mediated vasodilation in conscious dogs with heart failure.
Circ Res
73:
1013-1023,
1993
21.
Levine, B,
Kalman J,
Mayer L,
Fillit HM,
and
Packer M.
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.
N Engl J Med
323:
236-241,
1990[Abstract].
22.
Low, BC,
and
Grigor MR.
Angiotensin II stimulates system y+ and cationic amino acid transporter gene expression in cultured vascular smooth muscle cells.
J Biol Chem
270:
27577-27583,
1995
23.
Moncada, S,
Palmer RM,
and
Higgs EA.
Nitric oxide: physiology, pathophysiology, and pharmacology.
Pharmacol Rev
43:
109-142,
1991[ISI][Medline].
24.
Oddis, CV,
Simmons RL,
Hattler BG,
and
Finkel MS.
cAMP enhances inducible nitric oxide synthase mRNA stability in cardiac myocytes.
Am J Physiol Heart Circ Physiol
269:
H2044-H2050,
1995
25.
Scott, JA,
Machoun M,
and
McCormack DG.
Inducible nitric oxide synthase and vascular reactivity in rat thoracic aorta: effect of aminoguanidine.
J Appl Physiol
80:
271-277,
1996
26.
Simmons, WW,
Closs EI,
Cunningham JM,
Smith TW,
and
Kelly RA.
Cytokines and insulin induce cationic amino acid transporter (CAT) expression in cardiac myocytes. Regulation of L-arginine transport and no production by CAT-1, CAT-2A, and CAT-2B.
J Biol Chem
271:
11694-11702,
1996
27.
Song, W,
Lu X,
and
Feng Q.
Tumor necrosis factor-
induces apoptosis in cardiac myocytes via inducible nitric oxide synthase.
Cardiovasc Res
45:
595-602,
2000
28.
Wang, BY,
Ho HK,
Lin PS,
Schwarzacher SP,
Pollman MJ,
Gibbons GH,
Tsao PS,
and
Cooke JP.
Regression of atherosclerosis: role of nitric oxide and apoptosis.
Circulation
99:
1236-1241,
1999
29.
Wang, H,
Kavanauhg MP,
North RA,
and
Kabat D.
Cell-surface receptor for ecotropic murine retroviruses is a basic amino-acid transporter.
Nature
352:
729-731,
1991[Medline].
30.
Wong, H,
Anderson WD,
Cheng T,
and
Riabowol KT.
Monitoring mRNA expression by polymerase chain reaction: the "primer-dropping" method.
Anal Biochem
223:
251-258,
1994[ISI][Medline].
This article has been cited by other articles:
![]() |
Y. C. Luiking and N. E. P. Deutz Biomarkers of Arginine and Lysine Excess J. Nutr., June 1, 2007; 137(6): 1662S - 1668S. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Tran, X. Lu, M. Lei, Q. Feng, and Q. Wu Upregulation of corin gene expression in hypertrophic cardiomyocytes and failing myocardium Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1625 - H1631. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Peng, X. Lu, M. Lei, and Q. Feng Endothelial Nitric-oxide Synthase Enhances Lipopolysaccharide-stimulated Tumor Necrosis Factor-alpha Expression via cAMP-mediated p38 MAPK Pathway in Cardiomyocytes J. Biol. Chem., February 28, 2003; 278(10): 8099 - 8105. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Mann, D. L. Yudilevich, and L. Sobrevia Regulation of Amino Acid and Glucose Transporters in Endothelial and Smooth Muscle Cells Physiol Rev, January 1, 2003; 83(1): 183 - 252. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |